bms-986235 + itraconazole

**BMS-986235 + itraconazole** refers to the combination of BMS-986235, a selective small molecule agonist of formyl peptide receptor 2 (FPR2), and itraconazole, an antifungal agent and potent inhibitor of CYP3A4. BMS-986235 was developed for the resolution of inflammation, including in settings such as heart failure and myocardial infarction, by activating FPR2 to promote anti-inflammatory and proresolving mechanisms, especially via macrophage modulation and enhanced efferocytosis. Itraconazole is included experimentally or pharmacologically for its CYP3A4 inhibitory properties, most notably in clinical studies evaluating potential drug-drug interactions and effects on the pharmacokinetics and safety profile of BMS-986235. There is no evidence of clinical co-marketing or approval for this as a fixed-dose therapeutic combination; its use together has been limited to drug interaction studies in healthy subjects.